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Background: Vietnam achieved rapid scale-up of antiretroviral
therapy (ART), although external funds are declining sharply. To
achieve and sustain universal access to HIV services, evidence-based
planning is essential. To date, there had been limited HIV treatment
and care cost data available in Vietnam.
Methods: Cost data of outpatient and inpatient HIV care were extracted
at 21 sentinel facilities (17 adult and 4 pediatric) that epitomize the
national program. Step-down costing for administration costs and
bottom-up resource costing for drugs, diagnostics, and labor were used.
Records of 1401 adults and 527 pediatric patients were reviewed.
Results: Median outpatient care costs per patient-year for pre-ART,
first year ART, later year ART, and second-line ART were US $100,
US $316, US $303, and US $1557 for adults; and US $171, US $387,
US $320, and US $1069 for children, respectively. Median inpatient
care cost per episode was US $162 for adults and US $142 for children.
Non-antiretroviral (ARV) costs in adults at stand-alone facilities were
44% (first year ART) and 24% (later year ART) higher than those at
integrated facilities. Adults who started ART with CD4 count #100
cells per cubic millimeter had 47% higher non-ARV costs in the first
year ART than those with CD4 count .100 cells per cubic millimeter.
Adult ARV drug costs at government sites were from 66% to 85%
higher than those at donor-supported sites in the first year ART.
Conclusions: The study found that HIV treatment and care costs in
Vietnam are economical, yet there is potential to further promote
efficiency through strengthening competitive procurement, integrat-
ing HIV services, and promoting earlier ART initiation.
Key Words: antiretroviral therapy, HIV care, costing, integra-
tion, Vietnam
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INTRODUCTION
Vietnam has a concentrated HIV epidemic with esti-
mated HIV prevalence in the general population (age, 15–49
years) at 0.45% and the prevalence in people who inject drugs
at 13.4% in 2011.1 An estimated 248,500 people were living
with HIV in 20111 and 60,924 adults and children were
receiving antiretroviral therapy (ART) at the end of 2011.1
However, ART coverage compared with estimated needs
was still limited to 54%,1 and further scale-up is critical.
Vietnam’s national HIV response has relied on external
funds, such as President’s Emergency Funds for AIDS Relief
(PEPFAR) and Global Fund to fight AIDS, Tuberculosis, and
Malaria (GF). The National AIDS spending assessment reported
that 14.5% of total AIDS expenditure in 2009–2010 was
financed by domestic sources, 11.9% by private, and 73.7%
by international sources.1 Furthermore, Vietnam is transitioning
from a low-income country to a lower middle-income country as
per capita income reached US $1130 by the end of 2010.2 With
this transition, external funds for Vietnam’s HIV response
started to decline sharply. Careful planning is increasingly
important to achieve further scale-up and sustain access to essen-
tial HIV services. Although it is important to mobilize additional
domestic and international funds, evidence-guided policy deci-
sions to optimize resource allocations and promote cost-effective
service delivery are critical. However, there have been very
limited data on HIV treatment and care costs in Vietnam.
The purpose of this study was to provide the latest data on
HIV treatment and care costs in Vietnam from the health system
perspective to inform development of the national strategy,
forecast resource needs, and optimize service delivery models.
METHODS
Sites, Sampling, and Costing Period
Data were collected at 21 sentinel facilities (17 for adult
care and 4 for pediatric care) included in the annual national
HIV facility survey3 (see Table S1, Supplemental Digital
Content, http://links.lww.com/QAI/A441). The facilities
were chosen to epitomize the program in Vietnam and to
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reflect the diverse range of HIV treatment and care facilities.
Among adult care facilities, pre-ART and first-line ART serv-
ices were available at 16 facilities, whereas second- line ART
was available at only 5 facilities and inpatient care services at
8 facilities. Twelve adult outpatient clinics were integrated
facilities established within existing health facilities, that is,
hospitals and health centers, where HIV services were deliv-
ered along with other non-HIV health services. Four adult
outpatient clinics were stand-alone facilities providing only
HIV services, that is, provincial AIDS centers and some clin-
ics in Ho Chi Minh City (see Table S12, Supplemental
Digital Content, http://links.lww.com/QAI/A441).
At each adult site, the sample design required systematic
sampling of the medical records of 20 patients receiving pre-
ART or first-line ART services, 30 patients receiving second-
line ART, and 40 patients receiving inpatient care. At the 4
pediatric sites, the medical records of 30 children were
systematically sampled for each care phase. Sampling frames
consisted of the following: For pre-ART, a list of patients in pre-
ART status at the end of February 2010 who have had at least 1
visit in the last 12 months; for the first year of first-line ART
(ART year 1), a list of patients who started first-line ART during
the period from April 1, 2008, to March 31, 2009, excluding
transfer-in cases; for the second and later years of ART (ART
year 2+), a list of patients who started first-line ART before April
1, 2008, and who were neither lost to follow-up nor dead before
May 1, 2009 (ie, receiving at least 1 month of treatment during
the period from April 1, 2009, to March 31, 2010); for inpatient
care, a list of inpatients with confirmed HIV infection who were
discharged between April 1, 2009, and March 31, 2010.
Costs for pre-ART, ART year 2+, and second-line ART
phases were analyzed cross-sectionally, and the costs incurred
in the period from April 1, 2009, to March 31, 2010, were
estimated. For patients who entered into each phase after April
1, 2009, and those who left that care phase before March 31,
2010, cost information was collected only for the period they
were followed, but their cost estimates were annualized. ART
year 1 costs were analyzed as a cohort, for respective 12-month
periods (or until the patient died or was classified as lost) from
the date ART was initiated for each patient. The cohort-based
analysis was necessary for this phase because there is a greater
concentration of costs toward the first few months until treatment
is stabilized.4 The costing reference period of ART year 1 was
from April 2008 to March 2010, and approximately half of the
patient-months of treatment were in the preceding 12 months of
the costing period of the other phases; however, no obvious dif-
ference was identified in diagnostic tests or opportunistic infection
(OI) drugs used between earlier and later intake patients in this
phase. Inpatient costs covered the whole period of hospitalization.
During the costing period, stavudine (d4T) + lamivu-
dine (3TC) + nevirapine was the most commonly prescribed
ART regimen in Vietnam (Table 2), and the commonly per-
formed laboratory tests included CD4 lymphocyte count, liver
function test, complete blood count, and serological tests for
hepatitis B and hepatitis C.
Analysis of Costs and Treatment Outcomes
A hybrid of top-down and bottom-up costing approaches
was used, similar to the approach previously documented,5,6 to
overcome information constraints at facilities in resource-limited
settings. For antiretroviral (ARV) drugs, drugs to prevent or
treat OI drugs and diagnostic tests, quantities were extracted
from patient records and relevant prices were applied. For labor
and overhead costs (including annual capital costs), we estimated
total costs for the ward, clinic, or facility and divided by total
products to obtain unit costs, which were then applied to patients
based on the number of visits, inpatient days, or diagnostic serv-
ices used. For cases where health staff worked on a mix of
outpatient HIV treatment and other services, regardless of
whether working at integrated or stand-alone facilities, the
approximate share of time spent on different tasks was obtained,
and payroll costs were prorated accordingly. The overhead costs
included administrative and operational costs, for example, util-
ities, office supplies, rentals, repairs, and annual capital costs. For
the annual capital costs, the purchase value of equipment was
multiplied by a straight-line depreciation rate based on asset life
of 3–10 years following government regulations to obtain rough
estimates of equipment depreciation. All the costs were estimated
as year-2009 values, by using the annual payroll, overhead budg-
ets, service fees, and drug prices from 2009 as the unit costs,
which were then multiplied by the quantities obtained. This
constituted an implicit adjustment to 2009 prices for all care
phases, including ART year 1. Economic costs were not esti-
mated because relevant information needed to calculate the
opportunity costs of the resources used for HIV treatment, that
is, labor, equipment, land, and buildings, was not available. Costs
were converted using an average exchange rate over the costing
period of 18,462 Vietnam dong per United States dollar.7
The mean costs per patient-year or per episode were
weighted so that the proportion of cases in each facility type
(donor and health system level) in our sample was adjusted to be
proportional to total patients in these facility types nationwide
(details in the Appendix, see Tables S7 and S9, Supplemental
Digital Content, http://links.lww.com/QAI/A441). For adult pa-
tients, association between costs and facility or patient character-
istics was examined, including facility types (stand-alone and
integrated facilities), level of immunodeficiency, donor support,
and health system levels. Sensitivity analysis was performed for
the following scenarios: (1) Alternative approaches to annualize
adult pre-ART costs (many patients had less than 12-month fol-
low-up in pre-ART care); (2) effects of d4T phase-out on ART
year 1 costs (half of patient-months costed as ART year 1 phase
lies in the previous 12 months of other care phases); (3) potential
effects of incomplete recording of OI drugs prescribed. Statistical
analysis was performed using Wald test for 2-group compar-
ison, following a natural log transformation of cost values.
To assess potential association between the costs and
treatment outcomes at adult ART sites, retention rates on ART
at 12 months among patients who started ART in 2008 were
obtained from the annual national HIV facility survey. Data
were extracted from the ART register at each facility, and
retention rate was analyzed based on the month in which ART
was started and the month of attrition if it occurred, following
the procedure proposed by World Health Organization.8
Data Extraction and Ethics
Data were collected by a team of trained data extractors
using standardized data entry templates. A data set containing
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detailed labor and overhead data was compiled in MS Excel.
Patient record information was also compiled into databases
for each care phase. Data were analyzed using STATA
Version 11.0. To ensure confidentiality, data did not include
any names or addresses of the patients but only a code on the
sample frame. The study protocol was reviewed and approved
by the ethical review committee of the Hanoi School of
Public Health.
RESULTS
Size and Characteristics of Sampled Patients
The total number of people receiving ART at sampled
facilities at the end of September 2009 (midpoint of costing
period) was 8110 adults and 937 children, respectively, which
corresponds to 24% and 50% of total adults and children
receiving ART nationwide at that time. At the sampled
facilities, medical records of 1401 adult patients, consisting
of 305 in pre-ART, 332 in ART year 1, 323 in ART year 2+,
122 in second-line ART, and 319 in inpatient care; and the
records of 527 children, consisting of 104 in pre-ART, 104
in ART year 1, 120 in ART year 2+, 79 in second-line ART,
and 439 in inpatient care, were reviewed. From 48% to 83% of
sampled adults and from 51% to 61% of sampled children were
males, and the median ages of sampled adults and children
were in the range from 31 to 34 and from 3 to 8, respectively,
depending on the care phase.
Total Costs and Cost Components in Adults
and Children
In adults, median outpatient care cost per patient-year was
US $100 for pre-ART care, US $316 for ART year 1, US $303
for ART year 2+, and US $1557 for second-line ART (Table 1).
In children, median outpatient care cost per patient-year was US
$171 for pre-ART care, US $387 for ART year 1, US $320 for
ART year 2+, and US $1069 for second-line ART (Table 1).
Median inpatient care costs per episode were US $162 for
adults and US $142 for children.
In adults, during pre-ART care, the largest cost compo-
nent was diagnostics, which comprised 52% of the total costs
per patient-year. Once ART was initiated, the largest cost
component was ARV drugs, which accounted for 37%, 47%,
and 89% of the total costs per patient-year in ART year 1, ART
year 2+, and second-line ART (Table 1). OI drugs, diagnostics,
and labor costs, respectively, consisted of 10%–20% of total
costs in each ART phase. In contrast, in pediatric care, the
largest cost component was labor costs both in pre-ART and
ART phases, accounting for 45%–54% of total costs per
patient-year, except in second-line ART, for which ARV drug
cost was the largest component.
Factors Affecting Total Costs and Cost
Components in Adults
In adult ART year 1, ARV cost per patient-year was US
$210 at government sites, whereas it was only US $126 and
US $114 per patient-year at PEPFAR and GF-supported sites,
respectively (Table 2). For adult ART year 2+, ARV costs
were highest at government sites, but the difference among
the donors was smaller (Table 2). These differences are due to
different unit costs and prescription patterns among different
donors. The price of d4T + 3 TC + nevirapine per patient-year
procured by government sites was US $148, which was 1.6 and
1.5 times higher than the price paid by GF and PEPFAR,
respectively. The price of d4T + 3 TC+ efavirenz per patient-
year was US $355, which was 2.9 and 2.3 times higher than
the price paid by GF and PEPFAR projects. Zidovudine, teno-
fovir disoproxil fumrate, and efavirenz were used more com-
monly at PEPFAR and GF–supported sites than at Government
sites, especially in ART year 2+ (Table 2).
For tertiary and provincial facilities, GF sites had the
highest non-ARV costs in all ART phases (eg, ART year 1 cost
was US $253, US $278, and US $135 at PEPFAR, GF, and
government sites, respectively); but for the district facilities,
PEPFAR sites had higher non-ARV costs than GF sites
(US $251 and US $188 for ART year 1 at PEPFAR and GF
sites, respectively) (Table 2). In ART year 1 and year 2+, OI
drug and diagnostic costs were the largest non-ARV cost com-
ponents at PEPFAR and government sites, although labor cost
was the largest non-ARV cost component at GF sites (Table 2).
Overhead costs were much lower in PEPFAR sites compared
with GF and government sites (Table 2). The proportion of total
costs funded by external donors was highest at PEPFAR sites
followed by GF sites, for example, for adult ART year 1, 83%,
61%, and 6% of the total costs were funded by donors at
PEPFAR, GF, and government sites, respectively.
Mean non-ARV cost per patient-year at 4 stand-alone
sites was US $298 for year 1, which was 44% higher than that
at 12 integrated sites (P = 0.010), and was US $207 for year 2+,
which was also 24% higher (P = 0.065) (Fig. 1). Labor and
overhead costs were major causes of the higher costs at stand-
alone sites. In ART year 1, at stand-alone and integrated sites,
labor costs were US $111 and US $61, respectively (P = 0.010),
and overhead costs were US $76 and US $21, respectively (P,
0.001) (Fig. 1). The various parameters comparing stand-alone
and integrated sites are available in Table S12 (see Supplemen-
tal Digital Content, http://links.lww.com/QAI/A441).
Mean non-ARV costs in adult patients who had low CD4
(#100 cells/mm3) at initiation of ART were US $256 per
patient-year in ART year 1, which was 47% higher than those
who had higher CD4 count (.100 cells/mm3) (P = 0.027)
(Fig. 2). In each care phase, OI drug costs were from 2.0 to
3.9 times higher in patients with CD4 #100 cells per cubic
millimeter compared with those with CD4.100 cells per cubic
millimeter (P , 0.001, pre-ART and ART year 1; P = 0.706,
ART year 2+; P = 0.151, inpatient care) (Fig. 2).
The results of the sensitivity analysis are shown
in Table S11 (see Supplemental Digital Content,
http://links.lww.com/QAI/A441). Fifty-four percent of sampled
adult pre-ART patients had follow-up less than 12 month; when
pre-ART costs were calculated based on the actual follow-up
period instead of annualizing individual patient costs, median
costs per patient-year were 21% higher. When ART regimens
prescribed in year 1 were assumed to be the same as those
prescribed for ART year 2+ when the use of less-expensive
d4T was reduced, median costs per patient-year were 6% high-
er. If it was assumed that facilities having the OI drug costs in
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the lowest quartile had average OI drug costs of all the facilities
to address potential incomplete recording, the total costs
increased only 3% for pre-ART and 1% for ART year 1 and
ART year 2+ phases.
The average retention rate on ART at 12 months after
ART initiation among adult patients at the 16 studied
outpatient clinics was 86.3%. There was no correlation
between the ART year 1 costs and the retention rate at 12
months after ART initiation (Fig. 3), indicating that lower
cost per patient-year is not necessarily leading to poorer treat-
ment outcomes.
DISCUSSION
This study provides the first-ever evidence base for
nationwide HIV treatment and care costs in Vietnam. The
analysis showed that costs of HIV treatment and care delivery
in Vietnam are reasonable; however, it also suggests some
potential to further promote efficiency.
The present analysis suggests that HIV treatment and
care costs for adults in Vietnam are lower than most of those
reported in other published studies. According to a recent
systematic review, the median HIV treatment and care cost
per patient-year in low-income, lower middle-income, and
upper middle-income countries were US $ 792, US $932, and
US $1454, respectively.9 Cost analysis conducted in 2006–
2007 at 43 PEPFAR-supported outpatient clinics providing
HIV treatment reported that the median ART cost was at US
$880.10 In contrast, the present study showed that the median
cost per patient-year of first-line ART was US $316 for the
first year and US $303 for later years. Comparison of the
costing study results is often complex because of the meth-
odological differences. The costs are also affected signifi-
cantly by the year of studies because of factors such as the
decline in ARV drug price and growth in the number of
treated patients. Nevertheless, the data suggest that delivery
of HIV treatment and care in Vietnam is at least moderately
economical. Few studies have reported pediatric HIV treat-
ment and care costs from low- or middle-income countries. A
study from Brazil reported the cost of per child per year as US
$2039, and in Ethiopia yearly costs were US $961 for new
patients and US $933 for established patients.9 In contrast, the
present study found that median outpatient ART cost per
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OI drugs included drugs other than ARV drugs used in care for people living with HIV. The overhead costs included administrative operational costs, such as utilities, office
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pediatric patient-year was US $412 for the first year and US
$341 for later years, which are considerably lower than those
previously reported values.
Most ARV drugs procured by the government had higher
costs than the same drugs procured with external funds. In
Vietnam, ARV drugs funded by PEPFAR and GF are procured
through bidding by international procurement agencies. The
government also procures ARV drugs through bidding, but
international suppliers may not be fully involved. As the
government aims to increase reliance on domestic funding, it
seems critical for the government to strengthen ARV drug
procurement to obtain lower prices through international com-
petition. As Vietnam aims to further scale-up HIV treatment
access, these findings suggest the importance of rationalizing
resource allocation and strengthening care standards to deliver
quality services across different donors.
A recent systematic review reported that studies com-
paring costs at stand-alone and integrated services are scarce,
and thus at present no firm conclusion can be drawn whether
there are any economic benefits of integrating HIV treatment
into general health services.11 Our results suggest that non-
ARV costs are higher at stand-alone facilities than at integrated
facilities, and that labor costs and other indirect costs are the
major factors leading to these higher costs. These results are
probably because of the fact that facility capacity utilization is
higher at integrated facilities, as people attend facilities for
various health services, whereas only HIV patients attend
stand-alone facilities, and thus the unit indirect costs are smaller
at integrated sites. A potential explanation for lower labor costs
at integrated facilities is that health-care workers tend to have
multiple roles and spend part of their time delivering non-HIV
health services, resulting in lower labor unit cost per patient.
Our results confirmed that the care costs are higher in
patients with severe immunodeficiency. Higher care costs
associated with HIV disease progression have been docu-
mented by other studies.12–14 A review of 9 costing studies
showed that the costs are substantially higher at CD4 below
100 cells per cubic millimeter.13 It has also been shown that
early ART initiation before patients progress to advanced
immunodeficiency is associated with lower morbidity and
mortality15–18 and greater cost-effectiveness compared with
ART initiation at lower CD4 count.19 Furthermore, a recent
mathematical modeling study in Vietnam estimated that ear-
lier initiation of ART will prevent a substantial number of
new HIV infections and markedly reduce the need for ART in
the future.20 These lines of evidence suggest promoting earlier
TABLE 2. Cost Components of Adult Outpatient Care Costs Per Patient-Year, ARV Regimens, and Reliance on External Funds
Disaggregated by Donors










NA NA NA 126 114 210 143 174 179
Non-ARV drug costs—Tertiary and provincial facilities (in US $)
Total non-ARV
costs
108 65 145 253 278 135 150 196 119
OI drugs and
diagnostics
85 32 53 166 104 45 83 60 48
Labor 19 17 32 76 115 41 59 92 34
Overhead 4 16 60 11 59 48 8 44 37
Non-ARV drug costs—District facilities (US $)
Total non-ARV
costs
155 91 NA 251 188 NA 185 143 NA
OI drugs and
diagnostics
113 52 NA 144 70 NA 95 50 NA
Labor 31 24 NA 84 75 NA 69 58 NA
Overhead 11 15 NA 24 43 NA 21 35 NA
ART regimen use in first line, %
AZT/TDF-based
regimen
NA NA NA 11 9 3 29 58 2
EFV-based regimen NA NA NA 36 18 17 43 18 3
Proportion funded by external donors, %
Total costs 75 54 14 83 61 6 86 70 10
ARV drugs NA NA NA 100 100 0 100 100 0
OI drugs and
diagnostics
83 84 18 88 81 29 89 84 42
Labor 61 8 0 61 14 0 67 12 0
Overhead 0 0 0 0 0 0 0 0 0
No district-level facilities supported only by government funds were included in the study.
AZT, zidovudine; EFV, efavirenz; NA, not applicable; TDF, tenofovir disoproxil fumarate.
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ART initiation could potentially be cost-effective and cost
saving. Currently, late ART initiation is very common in
Vietnam with 52.7% of those who started ART in 2010 hav-
ing a CD4 count ,100 cells per cubic millimeter.1 Promoting
earlier uptake of HIV diagnosis and treatment through inter-
ventions and policy changes seems critical to achieve better
therapeutic, preventive, and economic outcomes.
Our study did not find a correlation between costs and
treatment outcomes measured by retention rate at 12 months,
suggesting some sites had good treatment outcomes (retention
rate .80% at 12 months) with relatively low costs (,US
$300 per patient-year). It would be worthwhile to further
investigate how these sites were able to achieve decent treat-
ment outcomes with relatively low financial inputs, which
may inform efficient service delivery models.
Our study has several limitations. First, some program
costs were not included, for example, costs related to training of
health care providers and technical assistance. Second, the
present study was conducted from a health system perspective,
and costs related to community-based services were not
included, although it was recognized that community-based
services play important roles in facilitating early access to HIV
treatment, and supporting adherence and retention. Third, some
sites had incomplete recording of clinical or financial data,
which posed challenges in the analysis, but efforts were made
to obtain more complete and accurate data through repeatedly
contacting the sites. Fourth, our study design did not allow
estimation of the aggregated costs of outpatient and inpatient
care, nor analysis of whether investment in outpatient care
might have any effects on inpatients costs. Fifth, sampling of
facilities was not completely random, thus our sample was not
representative of all facilities in the country. However, the
sampled facilities were selected to epitomize the national
program by including a diverse range of facilities across several
dimensions. Moreover, the total of sampled facilities accounted
for a substantial proportion of patients receiving ART nation-
wide (24% of adults and 50% of children) and, consequently,
we consider the findings of the study fairly robust. Sixth, the
costing reference period of ART year 1 only overlaps for half of
the person-months with other phases. This slightly reduces
comparability if there were any changes in patterns of service
inputs, whereas prices and unit costs applied to ART year 1
cases were the same as for other phases.
Despite the limitations, the study provides the most
comprehensive evidence base of the costs of delivering HIV
treatment and care for adults and children in Vietnam.
Although the study found that HIV treatment and care
delivery in Vietnam are already economical, it also found
potential to further improve efficiency; for example, through
strengthening competitive procurement of ARV drugs, inte-
grating HIV treatment and care into general health facilities,
and facilitating earlier ART initiation. The importance of
reducing reliance on external funds in some donor sites was
also highlighted. These findings are being used to inform the
Ministry of Health to mobilize alternative resources and to
FIGURE 1. Adult non-ARV costs per patient-year for outpatient
services at stand-alone and integrated facilities. Stand-alone
facilities (n = 4) are facilities that deliver only HIV services, and
integrated facilities (n = 12) are hospitals and district health cen-
ters where HIV services are delivered along with other health
services. Sample sizes are shown inside the columns. The follow-
ing costs were significantly different between the 2 groups: Total
non-ARV costs in ART year 1 (P = 0.010); labor costs in pre-ART
(P = 0.003), ART year 1 (P = 0.010), and ART year 2+ (P = 0.057);
overhead costs in pre-ART (P = 0.003), ART year 1 (P , 0.001),
and ART year 2+ (P, 0.001). OI drug and diagnostics costs were
not significantly different between 2 groups in any phase.
FIGURE 2. Adult non-ARV costs per
patient-year for outpatient and inpa-
tient care services disaggregated by
CD4 levels. Patients were stratified
according to the latest CD4 value for
pre-ART and inpatient care, and by
the CD4 at ART initiation for ART year
1 and ART year 2+ phases. The sample
sizes are shown inside each column.
The following costs were significantly
different between the 2 groups: Total
non-ARV costs in ART year 1 (P =
0.027); OI drug costs in pre-ART (P ,
0.001), ART year 1 (P , 0.001), and
inpatient care (P = 0.151). Labor, di-
agnostics, and overhead costs in all
phases were not significantly different
between the 2 groups.
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optimize the policy and program to establish efficient and
sustainable service delivery.
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FIGURE 3. ART retention at 12 months and costs per patient-
year (A, non-ARV costs; B, Total costs) at 16 adult outpatient
services. The ART retention rate at 12 months among those
started ART in 2008 was calculated following WHO patient
monitoring guidelines. The ART year 1 costs were estimated
for those starting ART between April 2008 and March 2009,
through sampling the patients as described in the text.
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